Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02978651
Other study ID # P16 04/ / BF2.649
Secondary ID 2016-002963-32
Status Withdrawn
Phase Phase 3
First received November 29, 2016
Last updated November 22, 2017

Study information

Verified date November 2016
Source Bioprojet
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The first objective of this study is to demonstrate the efficacy and safety of pitolisant given at 10, 20, or 40 mg per day versus placebo during 12 weeks of the Double Blind period, to treat the Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapy or treated by nCPAP but still complaining of EDS.

The secondary objectives of the study include assessing the long-term tolerance as well as the maintenance of efficacy of pitolisant given at 10, 20 or 40 mg per day during 39 weeks of Open Label Extension period.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date January 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria:

- Male and/or female outpatients aged from at least 18 years.

- Patients complaining of EDS refusing to be treated by nCPAP therapy or having been submitted to nCPAP therapy for a minimum period of 3 months, and still complaining of EDS despite the efforts made beforehand to obtain an efficient nCPAP therapy.

- Polysomnography performed (for patients submitted to nCPAP therapy - under nCPAP) between V1 and V2 or during the last 12 months with Apnea-Hypopnea Index (AHI): for patients without nCPAP therapy = 15; for patients under nCPAP therapy less or equal to 10.

- For patients submitted to nCPAP therapy: nCPAP = 4 hours / day (compliance checked on the clock-time counter of the CPAP machine)

- Mini Mental State Examination (MMSE) = 28

- Beck Depression Inventory - 13 items (BDI-13) score < 16 and item G (suicidal ideation) of BDI-13 = 0

- Body Mass Index (BMI) less or equal to 40 kg/m²

- Epworth Sleepiness Scale (ESS) = 12

- Female patients with child-bearing potential using a medically accepted method of birth control (i.e. oral contraceptives of normal average dosage) agreeing to continue this method throughout the study, and during the month following treatment discontinuation, being negative to serum pregnancy test performed at the screening visit.

- If specified by the investigator, the patient must be willing not to operate a car (if sleepy at wheel) or heavy machinery for the duration of the trial or as long as the investigator deems it clinically indicated. In addition, the patient should be willing to maintain during the study their usual behaviors which could affect their diurnal sleepiness (e.g. circadian rhythm, caffeine consumption, nocturnal sleep duration)

- Patients having signed and dated the informed consent form.

Exclusion Criteria:

- Patients suffering from chronic severe insomnia in accordance with the International Classification of Sleep Disorders (ICSD 2005) without OSA

- Patients with co-existing narcolepsy (ICSD 2005), judged on clinical criteria

- Patients with sleep debt not due to OSA (according to the physician' s judgment)

- Patients with non-respiratory sleep fragmentation (restless leg syndrome…)

- Shift work, professional drivers

- Refusal from the patient to stop any current therapy for EDS or predictable risk for the patient to stop the therapy

- Patients suffering from a psychiatric disease

- Acute or chronic disease preventing the improvement assessment, e.g. severe chronic obstructive pulmonary disease (COPD)

- Current or recent (within one year) history of drug, alcohol, narcotic or other substance abuse or dependence

- Any significant serious abnormality of the cardiovascular system, e.g. recent myocardial infarction, angina, hypertension or dysrhythmias (within the previous 6 months), Electrocardiogram Fridericia corrected QT interval higher than 450 ms, history of left ventricular hypertrophy or mitral valve prolapse

- Severe co-morbid medical or biological conditions that may jeopardize study participation at the discretion of the investigator (particularly in the cardiovascular system and the instable diabetes).

- Positive serology tests (HIV, HCV and HBsAg)

- Pregnant or breast-feeding women.

- Women with child-bearing potential and no efficient birth-control method

- Patients unable to understand the study protocol.

- Patients with suspected or known hypersensitivity to study medication

- Patients with a dominant arm deficiency impeding the achievement of the tests

- Patients using a prohibited medication.

- Congenital galactose poisoning, glucose and galactose malabsorption, deficit in lactase.

- Patients participating in another study or being in a follow-up period for another study.

Study Design


Intervention

Drug:
Pitolisant (BF2.649)

Placebo Oral Tablet


Locations

Country Name City State
France Laboratoire du sommeil Clinique de Physiologie, Sommeil et Exercice Pôle Thorax et Vaisseaux CHU de Grenoble Grenoble
France Hôpital Gui de Chauliac, CHU Montpellier, Unité des Troubles du Sommeil et de l'Eveil Montpellier

Sponsors (1)

Lead Sponsor Collaborator
Bioprojet

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Epworth sleepiness scale (ESS) Change from Baseline of ESS at 12 weeks and Change from Baseline of ESS at 52 weeks
Secondary Percentage of ESS responders at week 12 /52 versus baseline
Secondary Reduction of sleepiness and sleep episodes on the sleep diary at week 12 /52 versus baseline
Secondary Improvement in vigilance according to Oxford Sleep Resistance (OSleR) test at week 12 /52 versus baseline
Secondary European Quality of Life Questionnaire (EQ-5D) at week 12 /52 versus baseline
Secondary Leeds Sleep Evaluation Questionnaire (LSEQ) at week 12 /52 versus baseline
Secondary The Pichot Fatigue Scale at week 12 /52 versus baseline
Secondary Trail Making Test parts (A and B) at week 12 /52 versus baseline
Secondary Improvement in Clinical Global Impression (CGI) at week 12 /52 versus baseline
Secondary Z-score: composite score including ESS and OSLER results at week 12 /52 versus baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05857384 - Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs Phase 1
Recruiting NCT04547543 - Follow-up of Apneic Patients by Visio-consultation N/A
Recruiting NCT05371509 - Novel Myofunctional Water Bottle to Reduce OSA and Snoring Study N/A
Completed NCT02515357 - Mediterranean Diet/Lifestyle Intervention in Obstructive Sleep Apnea N/A
Completed NCT05582070 - Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction N/A
Active, not recruiting NCT03189173 - Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea Phase 2
Completed NCT04084899 - The Effect of CPAP on Lung Hyperinflation in Patients With OSA
Completed NCT03032029 - Registry on the Treatment of Central and Complex Sleep-Disordered Breathing With Adaptive Servo-Ventilation
Recruiting NCT04028011 - Clinical Evaluation of a Wearable Technology for the Diagnosis of Sleep Apnoea
Recruiting NCT06047353 - Community Health Advocates for Motivating PAP Use in Our Neighborhoods. N/A
Completed NCT05253963 - Acute Effect of CPAP on Weight in Patients With Obstructive Sleep Apnea N/A
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Completed NCT03589417 - Postural Stability, Balance and Fall Risk in Patients With Obstructive Sleep Apnea
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Withdrawn NCT04063436 - Evaluation of a New Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea N/A
Recruiting NCT05385302 - Sociological Determinants of Positive Airway Pressure Adherence in OSA Patients
Recruiting NCT04572269 - Metabolomics of Obstructive Sleep Apnea
Not yet recruiting NCT06467682 - 12-week Tele-exercise Program in Patients With OSA N/A
Withdrawn NCT04011358 - Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study N/A